Last reviewed · How we verify

NCT07253155

Probiotics Use and Preventing Gastrointestinal Symptoms in People Living With Overweight and Obesity.

ENROLLING BY INVITATION NA Last updated 28 November 2025
What this trial tests

NA trial testing Probiotic Arm in Gut Inflammation in 100 participants. Enrolling by invitation.

Timeline
14 October 2025
Primary endpoint
1 September 2028
1 September 2028

Quick facts

Lead sponsorUniversity of Ulster
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment100
Start date14 October 2025
Primary completion1 September 2028
Estimated completion1 September 2028
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Ulster

Who can join

18 and older, any sex, with Gut Inflammation or Overweight and Obese Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammatory bowel disease (IBD) affects over 6.8 million people worldwide, with current treatments often causing side effects and poor patient compliance. Dysbiosis of gut microbiota is a key factor, and while probiotics are considered safe and beneficial, conventional strains fail to function effectively during active inflammation due to high iron levels in the gut. Streptococcus thermophilus (FX856), unlike traditional probiotics, can thrive in this iron-rich environment, promoting mucosal healing. A 2-way crossover intervention study will be conducted with FX856 supplementation in overweight and obese individuals who often exhibit mild gut inflammation by measuring faecal calprotectin and systemic inflammatory markers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Probiotic Arm

Trials testing the same drug.

Other University of Ulster trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07253155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing